HUP0301003A2 - Kazeinből származó peptidek és terápiás alkalmazásuk - Google Patents

Kazeinből származó peptidek és terápiás alkalmazásuk

Info

Publication number
HUP0301003A2
HUP0301003A2 HU0301003A HUP0301003A HUP0301003A2 HU P0301003 A2 HUP0301003 A2 HU P0301003A2 HU 0301003 A HU0301003 A HU 0301003A HU P0301003 A HUP0301003 A HU P0301003A HU P0301003 A2 HUP0301003 A2 HU P0301003A2
Authority
HU
Hungary
Prior art keywords
peptides
therapy
casein
derived peptides
derived
Prior art date
Application number
HU0301003A
Other languages
English (en)
Inventor
Zvi Sidelman
Original Assignee
Chay 13 Medical Research Group N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chay 13 Medical Research Group N.V. filed Critical Chay 13 Medical Research Group N.V.
Publication of HUP0301003A2 publication Critical patent/HUP0301003A2/hu
Publication of HUP0301003A3 publication Critical patent/HUP0301003A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)

Abstract

A találmány tárgyát olyan biológiailag aktív peptidek képezik, melyeka tej kazein aSl frakciójának N-terminális részével azonosszekvenciákból származnak vagy ahhoz hasonlóak. Ezek a peptidekképesek az immunválasz stimulálására és fokozására, a vírusfertőzésselszembeni védekezésre a szérum koleszterinszintjének normalizálására ésa hematopoiezis stimulálására. A kazeinből származó peptidek nemtoxikusak, és az immunpatológiás állapotok, hiperkoleszterinémia,hematológiai rendellenességek és vírusokkal kapcsolatos megbetegedésekkezelésére és megelőzésére alkalmazhatók. Ó
HU0301003A 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy HUP0301003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13483000A IL134830A0 (en) 2000-03-01 2000-03-01 Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
PCT/IL2001/000198 WO2001064234A1 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy

Publications (2)

Publication Number Publication Date
HUP0301003A2 true HUP0301003A2 (hu) 2003-07-28
HUP0301003A3 HUP0301003A3 (en) 2007-08-28

Family

ID=11073892

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301003A HUP0301003A3 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy

Country Status (21)

Country Link
US (6) US20020147144A1 (hu)
EP (1) EP1261360B1 (hu)
JP (1) JP2003528827A (hu)
KR (1) KR20030025907A (hu)
CN (1) CN1427725A (hu)
AT (1) ATE451929T1 (hu)
AU (1) AU782662B2 (hu)
BR (1) BR0109027A (hu)
CA (1) CA2401550A1 (hu)
CZ (1) CZ20022915A3 (hu)
DE (1) DE60140794D1 (hu)
DK (1) DK1261360T3 (hu)
EA (3) EA007217B1 (hu)
HU (1) HUP0301003A3 (hu)
IL (2) IL134830A0 (hu)
MX (1) MXPA02008569A (hu)
NO (1) NO20024157L (hu)
NZ (1) NZ521016A (hu)
PL (1) PL361307A1 (hu)
WO (1) WO2001064234A1 (hu)
ZA (1) ZA200206842B (hu)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1694719A (zh) * 2001-08-30 2005-11-09 蔡13医疗研究团体有限公司 酪蛋白衍生的肽及其治疗用途
AU2003217337A1 (en) * 2002-02-06 2003-09-02 University Of North Carolina At Chapel Hill High-throughput cell identification and isolation method and apparatus
EP1359157A1 (en) * 2002-04-29 2003-11-05 Société des Produits Nestlé S.A. Metallo-proteinase inhibitory agent
EP1572115B1 (en) * 2002-11-27 2015-01-21 Ampio Pharmaceuticals, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
GB0313892D0 (en) * 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
CA2558155A1 (en) * 2004-03-01 2005-09-09 Zvi Sidelman Casein derived peptides and therapeutic uses thereof
AU2005235111B2 (en) 2004-03-30 2010-10-28 Monsanto Technology Llc Methods for controlling plant pathogens using N-phosphonomethylglycine
WO2005099724A2 (en) * 2004-04-13 2005-10-27 Parallel Solutions, Inc. Functionalized water-soluble polyphosphazene and uses thereof as modifiers of biological agents
US20060067976A1 (en) 2004-09-28 2006-03-30 Atrium Medical Corporation Formation of barrier layer
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9000040B2 (en) * 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
GB0423352D0 (en) * 2004-10-21 2004-11-24 Hannah Res Inst "Control of mammary cell number"
ES2400511T3 (es) * 2005-05-02 2013-04-10 Mileutis Ltd. Composiciones farmacéuticas que comprenden péptidos derivados de la caseina y métodos para el uso de las mismas
ES2319475B1 (es) * 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
CN101351554B (zh) 2005-10-04 2016-05-18 索利金尼克斯公司 包括通过调节先天免疫治疗和预防感染在内的治疗和预防免疫相关疾病的新型肽
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
GB2436328A (en) * 2006-03-22 2007-09-26 Regen Therapeutics Plc Peptide derived from colostrinin
EP1836906B1 (en) * 2006-03-24 2009-07-01 Unilever N.V. Healthy food product
EP1998853A1 (en) * 2006-03-24 2008-12-10 Unilever N.V. Healthy food product
SG175573A1 (en) * 2006-10-04 2011-11-28 Inimex Pharmaceuticals Inc Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
EP2124522B1 (en) * 2007-02-05 2011-11-16 National University of Singapore Putative cytokinin receptor and methods for use thereof
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
WO2009113635A1 (ja) * 2008-03-12 2009-09-17 株式会社 資生堂 不全角化抑制剤、毛穴縮小剤又は肌荒れ防止・改善剤及びそれを配合した皮膚外用組成物
CN102481233B (zh) * 2009-02-06 2014-07-30 宝洁公司 可崩解含水胶囊
JP2012523433A (ja) * 2009-04-10 2012-10-04 アブラクシス バイオサイエンス， エルエルシー ナノ粒子処方物およびその使用
JP5858906B2 (ja) 2009-05-04 2016-02-10 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 多孔質シリコン薬物溶出粒子
US10555527B2 (en) * 2009-05-18 2020-02-11 Monsanto Technology Llc Use of glyphosate for disease suppression and yield enhancement in soybean
GB0912481D0 (en) 2009-07-17 2009-08-26 Reckitt Benckiser Healthcare I Skincare compositions
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
WO2011081902A1 (en) * 2009-12-29 2011-07-07 W. R. Grace & Co.-Conn. Compositions for forming films having a desired degree of obscuration and methods of making and using the same
MX351010B (es) * 2010-02-04 2017-09-28 Isp Investments Inc Polimeros autoadaptables para formulaciones de filtro solar, anhidras.
CA2790023A1 (en) * 2010-02-18 2011-08-25 Athenix Corp. Axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230, and axmi231 delta-endotoxin genes and methods for their use
EP2536267B1 (en) 2010-02-18 2015-07-22 Athenix Corp. AXMI221z, AXMI222z, AXMI223z, AXMI224z, AND AXMI225z DELTA-ENDOTOXIN GENES AND METHODS FOR THEIR USE
PE20171378A1 (es) 2010-03-08 2017-09-15 Monsanto Technology Llc Moleculas polinucleotidicas para regulacion genetica en plantas
FR2958155B1 (fr) * 2010-04-02 2012-04-20 Oreal Composition de decoloration comprenant un sel peroxygene dans une base fortement riche en corps gras
WO2011137563A1 (en) 2010-05-07 2011-11-10 Unilever Plc High solvent content emulsions
MX2012014066A (es) 2010-06-04 2013-01-24 Monsanto Technology Llc Evento de brassica transgenica mon 88302 y metodos para su uso.
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
MX2013001740A (es) * 2010-08-19 2013-05-20 Pioneer Hi Bred Int Nuevo gen de bacillus thuringiensis con actividad lepidoptera
EP2632463B1 (en) * 2010-10-28 2018-04-04 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for their transdermal delivery
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
EP2635255B1 (en) 2010-11-01 2019-08-21 EyePoint Pharmaceuticals US, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
US20120311734A1 (en) * 2011-06-04 2012-12-06 The Texas A&M University System Potato transformation compositions, systems, methods, microorganisms, and plants
BR112014002988A2 (pt) * 2011-08-12 2017-03-01 Bayer Cropscience Nv expressão específica de célula de proteção de transgenes em algodão
MX350771B (es) 2011-09-13 2017-09-15 Monsanto Technology Llc Métodos y composiciones para el control de malezas.
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
ES2645927T3 (es) 2011-09-13 2017-12-11 Monsanto Technology Llc Procedimientos y composiciones para el control de malezas
MX362810B (es) 2011-09-13 2019-02-13 Monsanto Technology Llc Metodos y composiciones para controlar malezas.
MX343071B (es) 2011-09-13 2016-10-21 Monsanto Technology Llc Metodos y composiciones para el control de malezas.
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
EP2764046B1 (en) * 2011-10-05 2021-04-21 DuPont Nutrition USA, Inc. Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
US9492363B1 (en) * 2012-01-16 2016-11-15 American Spraytech, L.L.C. Aerosol sprayable color composition
MX2014008693A (es) * 2012-01-27 2014-08-27 Agile Therapeutics Inc Administracion transdermica de hormonas.
FR2988566B1 (fr) * 2012-03-28 2014-08-08 Yoplait France Compositions alimentaires pour stimuler la formation de tissu osseux
WO2013175480A1 (en) 2012-05-24 2013-11-28 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
CN104736177A (zh) * 2012-08-03 2015-06-24 Msm创新有限公司 用于肠道准备的方法和试剂盒
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
CN114891871A (zh) 2012-08-14 2022-08-12 10X基因组学有限公司 微胶囊组合物及方法
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US9617297B2 (en) * 2012-10-11 2017-04-11 The Regents Of The University Of California Apoplast wash fluid recovery for improved recombinant endoglucanase extraction in tabacco leaves
WO2014062989A2 (en) 2012-10-18 2014-04-24 Monsanto Technology Llc Methods and compositions for plant pest control
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2014093676A1 (en) 2012-12-14 2014-06-19 10X Technologies, Inc. Methods and systems for processing polynucleotides
US9206436B2 (en) * 2012-12-20 2015-12-08 Ut-Battelle, Llc Key gene regulating cell wall biosynthesis and recalcitrance in Populus, gene Y
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
WO2014106838A2 (en) 2013-01-01 2014-07-10 A.B. Seeds Ltd. Methods of introducing dsrna to plant seeds for modulating gene expression
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
BR112015019159A2 (pt) 2013-02-08 2017-07-18 10X Genomics Inc geração de código de barras de polinucleotídeos
US8961680B2 (en) * 2013-03-08 2015-02-24 Tbf Environmental Technology Inc. Solvent formulations
WO2014165108A1 (en) * 2013-03-12 2014-10-09 Psivida Us, Inc. Bioerodible silicon-based delivery vehicles for delivery of therapeutic agents
EP3604535A3 (en) 2013-03-13 2020-04-22 Monsanto Technology LLC Methods and compositions for weed control
EP2967082A4 (en) 2013-03-13 2016-11-02 Monsanto Technology Llc METHOD AND COMPOSITIONS FOR WEED CONTROL
US20140283211A1 (en) 2013-03-14 2014-09-18 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
US9289461B2 (en) * 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
WO2014151381A1 (en) 2013-03-15 2014-09-25 Psivida Us, Inc. Bioerodible silicon-based compositions for delivery of therapeutic agents
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
ES2806130T3 (es) * 2013-03-15 2021-02-16 Maria Beug Deeb Inc Dba T&M Ass Métodos y composiciones para la limpieza y desinfección de superficies
CA2817728A1 (en) * 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
US9777288B2 (en) 2013-07-19 2017-10-03 Monsanto Technology Llc Compositions and methods for controlling leptinotarsa
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
ES2927484T3 (es) * 2013-10-07 2022-11-07 Bristol Myers Squibb Holdings Ireland Formulación de tratamiento del VIH de atazanavir y cobicistat
EP3066200A1 (en) 2013-11-04 2016-09-14 Monsanto Technology LLC Compositions and methods for controlling arthropod parasite and pest infestations
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
WO2015108982A2 (en) 2014-01-15 2015-07-23 Monsanto Technology Llc Methods and compositions for weed control using epsps polynucleotides
ES2544153B1 (es) * 2014-02-24 2016-06-06 Ntd Labs, S.L. Uso de un hidrolizado de caseína como agente antiviral
US11091770B2 (en) 2014-04-01 2021-08-17 Monsanto Technology Llc Compositions and methods for controlling insect pests
DE202015009609U1 (de) 2014-04-10 2018-08-06 10X Genomics, Inc. Mikrofluidisches System zur Erzeugung von Emulsionen
EP3158067B1 (en) 2014-06-23 2020-08-12 Monsanto Technology LLC Compositions and methods for regulating gene expression via rna interference
WO2015200539A1 (en) 2014-06-25 2015-12-30 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
EP3161160B1 (en) 2014-06-26 2021-10-13 10X Genomics, Inc. Methods of analyzing nucleic acids from individual cells or cell populations
JP6640826B2 (ja) 2014-07-08 2020-02-05 ミメディクス グループ インコーポレイテッド 微粒子化ワルトン膠質
US20160022604A1 (en) * 2014-07-23 2016-01-28 Cadila Healthcare Limited Directly compressed ospemifene compositions
WO2016018887A1 (en) 2014-07-29 2016-02-04 Monsanto Technology Llc Compositions and methods for controlling insect pests
PL3191083T3 (pl) * 2014-09-11 2021-07-12 Gelita Ag Cząstki żelatyny/pektyny
JP6943761B2 (ja) 2014-09-17 2021-10-06 ロンザ，エルエルシー 活性化された過酸化水素消毒剤組成物
CA2964472A1 (en) 2014-10-29 2016-05-06 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
WO2016111285A1 (ja) * 2015-01-06 2016-07-14 山田　修 燃焼合成材料を利用した医薬組成物、血液処理装置、化粧料及び飲食品
AU2016207023B2 (en) 2015-01-12 2019-12-05 10X Genomics, Inc. Processes and systems for preparing nucleic acid sequencing libraries and libraries prepared using same
BR112017015705A2 (pt) 2015-01-22 2018-03-20 Monsanto Technology Llc composições e métodos para controle de leptinotarsa
EP3262407B1 (en) 2015-02-24 2023-08-30 10X Genomics, Inc. Partition processing methods and systems
KR20170119710A (ko) 2015-02-24 2017-10-27 10엑스 제노믹스, 인크. 표적화된 핵산 서열 커버리지 방법
CA2977961A1 (en) 2015-02-25 2016-09-01 The Procter & Gamble Company Fibrous structures comprising a surface softening composition
US20160303043A1 (en) * 2015-04-16 2016-10-20 Kate Somerville Skincare, LLC Self-foaming compositions and methods
AU2016270870A1 (en) 2015-06-02 2018-01-04 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
WO2016196782A1 (en) 2015-06-03 2016-12-08 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
JP6866343B2 (ja) 2015-07-10 2021-04-28 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ メタセシス化不飽和ポリオールエステルを含む布地ケア組成物
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
WO2017197338A1 (en) 2016-05-13 2017-11-16 10X Genomics, Inc. Microfluidic systems and methods of use
BR112019000371A2 (pt) * 2016-07-08 2019-04-24 The Gillette Company Llc composições líquidas para dispositivos de remoção de pelos que compreendem ésteres de poliol insaturados metatetizados
DE102016223333A1 (de) * 2016-11-24 2018-05-24 Henkel Ag & Co. Kgaa Alkalische Mittel zum Aufhellen von Haaren enthaltend Oxidationsmittel und spezielle Carbonsäureester als Keratinvernetzer
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
CN110214186B (zh) 2017-01-30 2023-11-24 10X基因组学有限公司 用于基于微滴的单细胞条形编码的方法和系统
ES2897024T3 (es) 2017-03-01 2022-02-28 Arena Pharm Inc Composiciones que comprenden agonistas del receptor de PGI2 y procesos para la preparación de las mismas
US10398670B2 (en) * 2017-04-24 2019-09-03 Knoze Jr. Corporation Oral microbiota promotion for oral and/or sinus infections
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
CN109526228B (zh) 2017-05-26 2022-11-25 10X基因组学有限公司 转座酶可接近性染色质的单细胞分析
US10471033B2 (en) * 2017-09-15 2019-11-12 Knoze Jr. Corporation Oral microbiota promotion for immune system associated inflammations
SG11201913654QA (en) 2017-11-15 2020-01-30 10X Genomics Inc Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
CN112262218A (zh) 2018-04-06 2021-01-22 10X基因组学有限公司 用于单细胞处理中的质量控制的系统和方法
WO2021055366A1 (en) * 2019-09-16 2021-03-25 Kiverdi, Inc. Microbial protein hydrolysate compositions and methods of making same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764670A (en) * 1970-10-28 1973-10-09 Ministry Of Agriculture Polypeptidic anti-biotic substances derived from casein
US3778426A (en) * 1970-12-16 1973-12-11 Research Corp Therapeutically useful polypeptides
US4636384A (en) * 1982-06-03 1987-01-13 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5344820A (en) * 1987-05-15 1994-09-06 Snow Brand Milk Products Co., Ltd. Infection protectant
JP2631470B2 (ja) * 1987-05-15 1997-07-16 雪印乳業株式会社 感染防御剤
JP2805490B2 (ja) * 1989-02-07 1998-09-30 雪印乳業株式会社 細菌毒素中和剤
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
FR2686085B1 (fr) * 1992-01-10 1995-08-04 Agronomique Inst Nat Rech Peptides representant des fragments du cmp, anticorps diriges contre lesdits peptides, et leurs utilisations.
GB9310472D0 (en) * 1993-05-20 1993-07-07 Univ Warwick Phenylalanine-free protein and dna coding thereof
TW282398B (hu) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co
US5707968A (en) * 1994-05-26 1998-01-13 Abbott Laboratories Inhibition of attachment of H.influenzae to human cells
US5506209A (en) * 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5538952A (en) * 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5712250A (en) * 1994-09-16 1998-01-27 Abbott Laboratories Product for inhibition of human rotavirus infection
KR0140248B1 (ko) * 1995-03-23 1998-06-15 한상기 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법
US5985275A (en) * 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
US6570060B2 (en) * 1995-05-16 2003-05-27 Mclachlan Corran Norman Stuart Milk lacking β-casein A1
KR100221124B1 (ko) * 1996-09-23 1999-10-01 한상기 신규한 카제인 및 그 제조방법
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
JP4191261B2 (ja) * 1997-03-21 2008-12-03 雪印乳業株式会社 鉄カゼイン類分解物複合体及びその製造法
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
ATE256185T1 (de) * 1997-08-29 2003-12-15 Brigham & Womens Hospital T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
AUPP051497A0 (en) * 1997-11-24 1997-12-18 University Of Melbourne, The Antimicrobial peptides
US5985575A (en) * 1998-05-20 1999-11-16 Wisconsin Alumni Research Foundation Tethered function assay for protein function
US6570606B1 (en) * 1998-05-29 2003-05-27 3Com Corporation Method and apparatus for controlling transmission of media signals over a data network in response to triggering events at participating stations
CN1230444C (zh) * 1998-11-16 2005-12-07 德克萨斯州立大学董事会 含有hiv细胞毒t淋巴细胞表位的hiv多肽或肽或其多聚核苷酸表达构建体的用途
GB9927603D0 (en) * 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
IL138946A0 (en) * 2000-10-11 2001-11-25 Compugen Ltd Method for the identification of peptides and proteins
EP1928473A4 (en) * 2005-09-28 2009-11-18 Dnp Canada Inc COMBINATION OF POLYCHITOSAMINE AND FIBRATE FOR THE PREVENTION AND TREATMENT OF HYPERLIPIDEMIA
US8865876B2 (en) * 2008-06-02 2014-10-21 California Institute Of Technology Engineered lectin oligomers with antiviral activity

Also Published As

Publication number Publication date
NO20024157L (no) 2002-10-30
KR20030025907A (ko) 2003-03-29
US8735348B2 (en) 2014-05-27
IL151351A (en) 2012-04-30
AU782662B2 (en) 2005-08-18
PL361307A1 (en) 2004-10-04
US20100298216A1 (en) 2010-11-25
DE60140794D1 (de) 2010-01-28
EA200401467A1 (ru) 2005-04-28
EA005579B1 (ru) 2005-04-28
BR0109027A (pt) 2003-06-03
US20020147144A1 (en) 2002-10-10
CA2401550A1 (en) 2001-09-07
WO2001064234A1 (en) 2001-09-07
EP1261360A1 (en) 2002-12-04
US20100317601A1 (en) 2010-12-16
HUP0301003A3 (en) 2007-08-28
EA200400376A1 (ru) 2005-06-30
NO20024157D0 (no) 2002-08-30
AU3596201A (en) 2001-09-12
JP2003528827A (ja) 2003-09-30
US7741274B2 (en) 2010-06-22
ZA200206842B (en) 2003-07-28
EP1261360B1 (en) 2009-12-16
DK1261360T3 (da) 2010-05-03
IL134830A0 (en) 2001-05-20
EA007217B1 (ru) 2006-08-25
EA007814B1 (ru) 2007-02-27
MXPA02008569A (es) 2003-02-24
EA200200820A1 (ru) 2003-08-28
EP1261360A4 (en) 2004-03-10
CN1427725A (zh) 2003-07-02
CZ20022915A3 (cs) 2003-03-12
NZ521016A (en) 2005-08-26
US20070161557A1 (en) 2007-07-12
US20090192081A1 (en) 2009-07-30
US20130096073A1 (en) 2013-04-18
ATE451929T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
HUP0301003A2 (hu) Kazeinből származó peptidek és terápiás alkalmazásuk
EA200601575A1 (ru) Казеиновые пептиды и их терапевтическое применение
GEP20022695B (en) Moraxella Catarrhalis Outer Membrane Protein-106 Polypeptide, Gene Sequence and Uses Thereof
HUP0301789A2 (hu) Rekombináns anti CD40 ellenanyagok és használatuk
HUP0100627A1 (hu) Amiloidogén betegségek megelőzése és kezelése
DE60142683D1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
DK1095061T3 (da) Peptider baseret på sekvensen af humant lactoferring og deres anvendelse
DE69718150D1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
GB2367061A (en) Peptides
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
DE60232862D1 (de) Rekombinantes pockenvirus für chimäre proteine des menschlichen immunschwächevirus
DE60223037D1 (de) Chitin-mikropartikel und ihre medizinische verwendung
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
DE69834194D1 (de) Oberfläche-exponierte proteine von chlamydia pneumoniae
HUP0302233A2 (hu) Virális betegségek kezelésére IL-18-cal és IL-18 kombinációkkal
SI1173194T1 (en) Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation
DE60024259D1 (de) Trennung eines humanen retrovirus
HUP0200162A2 (hu) Haemophilus somnus transzferrin-kötő fehérjék klónozása és expresszálása
MD2053B1 (en) Remedy with interferon inducing action
EP2025754A3 (en) Moraxella (Branhamella) catarrhalis antigens
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
ATE386542T1 (de) Mittel zur stimulation des immunsystems
MXPA03004436A (es) Proteinas bcl-2 mutantes y sus usos.
WO2001087961A1 (fr) Nouveau polypeptide, proteine pax humaine 11.4, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: PEPTERA PHARMACEUTICALS LTD., IL

Free format text: FORMER OWNER(S): CHAY 13 MEDICAL RESEARCH GROUP N.V., NL

FD9A Lapse of provisional protection due to non-payment of fees